The Ranitidine Tablets, cataloged under National Stock Number 6505-01-160-7702, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Glaxo Wellcome Inc. Government technical data includes 4 specifications, cited from the U.S. Government catalog. The record lists 8 manufacturer part numbers for this item, enabling identification through both NSN and commercial part number lookups. 3 additional reference documents (drawings, advisory and superseded references) are recorded in the U.S. Government catalog. 1 item shares a part number with this NSN in the catalog (possible match — not a government interchangeability claim). Current acquisition status: Active.
| Parameter | Value |
|---|---|
| NSN | 6505-01-160-7702 |
| Primary Part Number | NDC00173-0344-42 |
| Item Name | Ranitidine Tablets |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Glaxo Wellcome Inc |
| Status | ACTIVE |
| Primary Container Content Quantity | 60.000 TABLETS |
| Medical Designation and Grade | UNITED STATES PHARMACOPEIA |
| Primary Container Type | BOTTLE |
| Active Medicament Medicinal Strength | 150.000 MILLIGRAMS RANITIDINE EQUIVALENT |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Part Number | Manufacturer |
|---|---|
| 1525-534 | Sandoz (BEL) |
| ZANTAC 150 COMP 56 X 150MG | Glaxosmithkline Pharmaceuticals (BEL) |
| RANITIDINE SANDOZ 60X150MG | Sandoz (BEL) |
| NDC00173-0344-42 PRIMARY | Glaxo Wellcome Inc (USA) |
| RANITIDINE EG 150MG X 56 COMP | Eurogenerics S.a. (BEL) |
| NDC55289-0319-60 PRIMARY | Pd-Rx Pharmaceuticals, Inc. (USA) |
| DOCRANITI 150MG 56 COMP | Docpharma N.v. (BEL) |
| NDC65162-0253-06 PRIMARY | Amneal Pharmaceuticals of New York, Llc (USA) |
| Reference | Meaning |
|---|---|
| 1487016 | 6/9 Informative reference only Association Pharmaceutique Belge-Algemene Pharmaceutische Bond |
| ZANTAC TABLETS | 5/1 Secondary reference Glaxo Wellcome Inc |
| 1525534 | 6/9 Informative reference only Association Pharmaceutique Belge-Algemene Pharmaceutische Bond |
NSN 6505-01-160-7702 is a Ranitidine Tablets, manufactured by Glaxo Wellcome Inc, classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-160-7702 has 8 manufacturer part numbers on file: 1525-534 (Sandoz), ZANTAC 150 COMP 56 X 150MG (Glaxosmithkline Pharmaceuticals), RANITIDINE SANDOZ 60X150MG (Sandoz), NDC00173-0344-42 (Glaxo Wellcome Inc), RANITIDINE EG 150MG X 56 COMP (Eurogenerics S.a.) and 3 more.
1 possible match (shared part number, not a government interchangeability claim): 4720-01-436-0696. Verify interchangeability with system specifications before substitution.
Key specifications for NDC00173-0344-42: Primary Container Content Quantity: 60.000 TABLETS; Medical Designation and Grade: UNITED STATES PHARMACOPEIA; Primary Container Type: BOTTLE; Part Name Assigned by Controlling Agency: RANITIDINE TABLETS USP 150MG 60S BT. 4 specifications are documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.